Publication details
Léčba obinutuzumabem je možná i u velmi starých pacientů s chronickou lymfocytární leukemií
| Title in English | Obinutuzumab treatment is possible even in very old patients with chronic lymphocytic leukemia |
|---|---|
| Authors | |
| Year of publication | 2016 |
| Type | Article in Periodical |
| Magazine / Source | Acta medicinae |
| MU Faculty or unit | |
| Citation | |
| Field | Oncology and hematology |
| Keywords | age; chronic lymphocytic leukemia; obinutuzumab |
| Description | Obinutuzumab is humanized anti-CD20 monoclonal antibody recently approved for chronic lymphocytic leukemia (CLL) therapy. Obinutuzmab has strong antibody dependent cellular cytotoxicity and can directly induce cell death. This antibody in combination with chlorambucil can be used in elderly and comorbid CLL patients not suitable for fludarabine treatment. Our report shows case of 86 years-old lady treated successfully by obinutuzumab plus chlorambucil regimen. This treatment is effective with no side effects despite high age of the patient and despite TP53 defect which has been found in patient CLL cells. |